Musculoskeletal pain | VLD CBP | 2.3 (1.2) | 1.7 (1.2) | –0.6 | –26.1 | 0.88 | 0.010† | 0.044† | –18.2 |
| Placebo | 2.1 (1.2) | 2.1 (1.4) | 0 | 0.0 | 0.83 | 1.000 | | |
Fatigue | VLD CBP | 5.0 (1.3) | 4.3 (1.5) | –0.7 | –14.0 | 1.33 | 0.039† | 0.126 | –12.4 |
| Placebo | 4.7 (1.2) | 4.9 (1.4) | 0.2 | 4.3 | 1.82 | 0.647 | | |
Tenderness | VLD CBP | 14.3 (5.6) | 18.6 (9.5) | 4.3 | 30.1 | 5.76 | 0.006† | 0.029† | 16.7 |
| Placebo | 15.6 (10.1) | 16.1 (7.7) | 0.5 | 3.2 | 4.13 | 0.614 | | |
HAD score | VLD CBP | 13.7 (5.8) | 10.4 (7.5) | –3.3 | –24.1 | 4.96 | 0.012† | 0.067 | –32.0 |
| Placebo | 15.7 (7.4) | 15.1 (8.9) | –0.6 | –3.8 | 3.36 | 0.459 | | |
HAD depression | VLD CBP | 6.3 (3.9) | 4.9 (4.5) | –1.4 | –22.2 | 2.25 | 0.017† | 0.023† | –38.5 |
| Placebo | 6.7 (4.1) | 7.4 (4.7) | 0.7 | 10.4 | 2.89 | 0.319 | | |
Patient-rated change in fatigue | VLD CBP | | | 2.9 | | 1.00 | 0.001† | 0.133 | |
| Placebo | | | 2.5 | | 1.29 | 0.120 | | |
Clinician-rated change in fatigue | VLD CBP | | | 2.8 | | 1.04 | 0.003† | 0.257 | |
| Placebo | | | 2.5 | | 1.15 | 0.083 | | |